Fund Overview
The State Street SPDR S&P Biotech ETF, identified by the ticker XBI, operates within the Health sector and is managed by State Street Investment Management. This fund currently oversees a substantial pool of capital with total assets under management reaching $8.06B, a figure that indicates significant scale and widespread popularity among market participants seeking exposure to the biotechnology industry. While the specific number of holdings is not publicly disclosed in the available data, the fund's classification as an ETF implies a structure designed to track an index, though the exact count of underlying securities remains N/A. The fund charges an expense ratio of 0.3%, which positions it as a relatively low-cost investment vehicle compared to many actively managed peers that often carry fees exceeding one percent.
Performance Analysis
The current yield for the XBI is recorded at 0.3%, a metric that suggests the fund distributes a very small portion of its income to shareholders, making it less attractive for income-seeking investors who prioritize regular dividends over capital appreciation. Year-to-date performance shows a return of 4.5%, reflecting the fund's recent price action relative to its starting valuation for the current calendar year. Looking at the longer horizon, the 3-year average return stands at 17.1%, indicating a period of positive compound growth, whereas the 5-year average return is -2.0%, which highlights a divergence in performance over different timeframes. The contrast between the positive 3-year average and the negative 5-year average suggests that the fund's recent performance has been driven by recent market conditions that have not yet been fully reflected in the five-year rolling average. The expense ratio of 0.3% compounds annually over time, meaning that for a long-term holder, these costs will gradually erode the gross returns generated by the underlying portfolio, thereby reducing the net return available to the investor.
Price & Risk Profile
The 52-week high for the XBI is $132.09, while the 52-week low is $66.66, establishing a trading range of approximately $65.43. This wide fluctuation between the high and low prices indicates a high degree of price volatility typical of the biotechnology sector, where earnings and clinical trial results can cause sharp price swings. Based on the provided metrics, the current price sits somewhere between the 52-week high of $132.09 and the 52-week low of $66.66, though the exact current trading price is not listed in the source data. The beta value is listed as N/A, meaning that a specific measure of volatility relative to the broader market index is not available for this fund in the provided facts. Consequently, the overall risk profile must be inferred primarily from the substantial price range observed over the past year, which suggests that the asset class carries significant inherent risk and is sensitive to market shifts. The absence of a cited beta prevents a direct quantitative comparison to the S&P 500, but the historical price action confirms that the fund experiences substantial price movement that could impact portfolio stability.